Summary of Key Points Core Viewpoint - The company has decided to change the funding method for certain investment projects from providing loans to its subsidiary to increasing capital in the subsidiary, utilizing its own funds for this purpose [1][7][10]. Group 1: Fundraising Overview - The company raised a total of RMB 1,216,511,427.60 through its initial public offering, with a net amount of RMB 1,110,744,306.58 after deducting issuance costs [1][5]. - The funds were deposited into a special account approved by the company's board of directors, and a tripartite supervision agreement was signed with the sponsor and the commercial bank [1][8]. Group 2: Investment Project Details - The net amount raised will be allocated to various investment projects, including a high-end pharmaceutical product project and a pharmaceutical intermediate project [5][6]. - The company plans to invest RMB 43,886.66 million in the pharmaceutical intermediate project, with a portion of this amount being changed from a loan to a capital increase [6][7]. Group 3: Capital Increase Implementation - The company will increase its investment in its wholly-owned subsidiary, Jin Kai Pharmaceutical, by RMB 32,886.66 million and an additional RMB 1,913.34 million from its own funds [6][7]. - Following this capital increase, the registered capital of Jin Kai Pharmaceutical will rise from RMB 15,000.00 million to RMB 49,800.00 million [6][7]. Group 4: Management and Oversight - The company has established a special account for the management of raised funds and will adhere to relevant regulations to ensure the safety of these funds [8][10]. - The board of directors and the supervisory board have both approved the change in funding method, affirming that it aligns with legal requirements and benefits the company's long-term development [10][11].

Company Overview - Sital's stock closed at 11.81 yuan on August 20, down 0.35 yuan, a decrease of 2.88% from the previous trading day [1] - The company operates in the chemical pharmaceutical sector, focusing on the research, production, and sales of pharmaceutical intermediates, active pharmaceutical ingredients, and formulations [1] - Sital is recognized as a specialized and innovative enterprise in Zhejiang Province [1] Stock Performance - On August 20, Sital's stock opened at 12.26 yuan, reaching a high of 12.26 yuan and a low of 11.63 yuan, with a trading volume of 448,000 hands and a transaction amount of 530 million yuan [1] - The stock experienced a rapid rebound in the morning session, with a price of 12.05 yuan reported at 9:35 AM, showing an increase of over 2% within 5 minutes, and a transaction amount of 113 million yuan at that time [1] Capital Flow - On August 20, the net inflow of main funds was 27.538 million yuan, accounting for 0.53% of the circulating market value [1] - Over the past five trading days, the cumulative net inflow of main funds reached 81.2404 million yuan, representing 1.57% of the circulating market value [1]

Group 1 - The stock price of Fujilai as of August 11, 2025, closed at 37.44 yuan, down 0.58% from the previous trading day [1] - The trading volume on that day was 47,322 lots, with a transaction amount of 176 million yuan [1] - Fujilai's main business includes the research, production, and sales of pharmaceutical intermediates, active pharmaceutical ingredients, and formulations, primarily used in oncology, antiviral, and cardiovascular fields [1] Group 2 - As of July 31, 2025, the total number of shareholders for Fujilai was 13,377 [1] - The company is currently implementing a share repurchase plan, with further details to be announced in subsequent announcements [1] - On August 11, 2025, the net inflow of main funds was 2.2474 million yuan, with a cumulative net inflow of 31.5657 million yuan over the past five days [1]

Group 1 - The stock price of Tianyu Co., Ltd. closed at 25.65 yuan on August 5, 2025, down by 0.15 yuan, a decrease of 0.58% from the previous trading day [1] - The trading volume on that day was 35,396 hands, with a transaction amount of 0.91 billion yuan, and a fluctuation of 2.17% [1] - Tianyu Co., Ltd. operates in the chemical pharmaceutical industry, focusing on the research, production, and sales of pharmaceutical intermediates, active pharmaceutical ingredients, and formulations [1] Group 2 - The company’s products cover multiple therapeutic areas, including antihypertensive, antihyperlipidemic, and antidiabetic treatments [1] - For the first half of 2025, the company expects a net profit attributable to shareholders of 1.3 billion to 1.8 billion yuan, representing a year-on-year growth of 144.29% to 238.25% [1] - On August 5, 2025, the net outflow of main funds was 5.96 million yuan, accounting for 0.11% of the circulating market value [1]